# A Study of Nintedanib for LymphAngioleioMyomatosis (LAM)

> **NCT03062943** · PHASE2 · COMPLETED · sponsor: **IRCCS Multimedica** · enrollment: 30 (actual)

## Conditions studied

- Lymphangioleiomyomatosis

## Interventions

- **DRUG:** Nintedanib

## Key facts

- **NCT ID:** NCT03062943
- **Lead sponsor:** IRCCS Multimedica
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-06
- **Primary completion:** 2021-12
- **Final completion:** 2021-12
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03062943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03062943, "A Study of Nintedanib for LymphAngioleioMyomatosis (LAM)". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT03062943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*